BioPharma Dive - Latest News

‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public in a challenging market for biotech stocks.

Feb 14, 2025 - 17:53
 0
‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public in a challenging market for biotech stocks.

Read More

Tags:

Previous Article

It's A $15,000 Honda S2000 With One Photo And Obvious Mods, What's The Worst Tha...

Next Article

Trump administration to fire thousands at health agencies

Related Posts

Blocking PD-1 and VEGF: The bispecific cancer drugs that could best Keytruda

Blocking PD-1 and VEGF: The bispecific cancer drugs tha...

Mar 4, 2025  0

Startup Glycomine raises $115M to push rare disease drug deeper into testing

Startup Glycomine raises $115M to push rare disease dru...

Apr 16, 2025  0

Novo’s Wegovy successor disappoints in second large trial

Novo’s Wegovy successor disappoints in second large trial

Mar 10, 2025  0